Halozyme Therapeutics (HALO) Free Cash Flow Growth (5y) (2015 - 2026)
Halozyme Therapeutics (HALO) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Halozyme Therapeutics | 9.65 Bn | 9.33 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.89% |
| Dec 31, 2025 | 33.35% |
| Sep 30, 2025 | 100.38% |
| Jun 30, 2025 | 94.96% |
| Mar 31, 2025 | 99.40% |
| Dec 31, 2024 | 55.29% |
| Sep 30, 2024 | 42.76% |
| Jun 30, 2024 | 33.17% |
| Mar 31, 2024 | 96.40% |
| Dec 31, 2023 | 52.19% |
| Sep 30, 2023 | 53.35% |
| Jun 30, 2023 | 42.04% |
| Mar 31, 2023 | 41.56% |
| Dec 31, 2022 | -12.20% |
| Sep 30, 2022 | 27.56% |
| Jun 30, 2022 | 33.68% |
| Mar 31, 2022 | 32.64% |
| Dec 31, 2021 | 48.27% |
| Sep 30, 2021 | 72.38% |
| Jun 30, 2021 | 35.66% |